Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Research Report 2024
Report Overview:
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size was estimated at USD 808.69 million in 2023 and is projected to reach USD 1108.72 million by 2029, exhibiting a CAGR of 5.40% during the forecast period.
This report provides a deep insight into the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market in any manner.
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market Segmentation (by Type)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market Segmentation (by Application)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Geographic Segmentation
• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
• Overview of the regional outlook of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market:
Key Reasons to Buy this Report:
• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Markets Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size was estimated at USD 808.69 million in 2023 and is projected to reach USD 1108.72 million by 2029, exhibiting a CAGR of 5.40% during the forecast period.
This report provides a deep insight into the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, Porter’s five forces analysis, value chain analysis, etc.
The analysis helps the reader to shape the competition within the industries and strategies for the competitive environment to enhance the potential profit. Furthermore, it provides a simple framework for evaluating and accessing the position of the business organization. The report structure also focuses on the competitive landscape of the Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market, this report introduces in detail the market share, market performance, product situation, operation situation, etc. of the main players, which helps the readers in the industry to identify the main competitors and deeply understand the competition pattern of the market.
In a word, this report is a must-read for industry players, investors, researchers, consultants, business strategists, and all those who have any kind of stake or are planning to foray into the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market in any manner.
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market: Market Segmentation Analysis
The research report includes specific segments by region (country), manufacturers, Type, and Application. Market segmentation creates subsets of a market based on product type, end-user or application, Geographic, and other factors. By understanding the market segments, the decision-maker can leverage this targeting in the product, sales, and marketing strategies. Market segments can power your product development cycles by informing how you create product offerings for different segments.
Key Company
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Market Segmentation (by Type)
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Market Segmentation (by Application)
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Geographic Segmentation
• North America (USA, Canada, Mexico)
• Europe (Germany, UK, France, Russia, Italy, Rest of Europe)
• Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Rest of Asia-Pacific)
• South America (Brazil, Argentina, Columbia, Rest of South America)
• The Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria, South Africa, Rest of MEA)
Key Benefits of This Market Research:
• Industry drivers, restraints, and opportunities covered in the study
• Neutral perspective on the market performance
• Recent industry trends and developments
• Competitive landscape & strategies of key players
• Potential & niche segments and regions exhibiting promising growth covered
• Historical, current, and projected market size, in terms of value
• In-depth analysis of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
• Overview of the regional outlook of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market:
Key Reasons to Buy this Report:
• Access to date statistics compiled by our researchers. These provide you with historical and forecast data, which is analyzed to tell you why your market is set to change
• This enables you to anticipate market changes to remain ahead of your competitors
• You will be able to copy data from the Excel spreadsheet straight into your marketing plans, business presentations, or other strategic documents
• The concise analysis, clear graph, and table format will enable you to pinpoint the information you require quickly
• Provision of market value (USD Billion) data for each segment and sub-segment
• Indicates the region and segment that is expected to witness the fastest growth as well as to dominate the market
• Analysis by geography highlighting the consumption of the product/service in the region as well as indicating the factors that are affecting the market within each region
• Competitive landscape which incorporates the market ranking of the major players, along with new service/product launches, partnerships, business expansions, and acquisitions in the past five years of companies profiled
• Extensive company profiles comprising of company overview, company insights, product benchmarking, and SWOT analysis for the major market players
• The current as well as the future market outlook of the industry concerning recent developments which involve growth opportunities and drivers as well as challenges and restraints of both emerging as well as developed regions
• Includes in-depth analysis of the market from various perspectives through Porter’s five forces analysis
• Provides insight into the market through Value Chain
• Market dynamics scenario, along with growth opportunities of the market in the years to come
• 6-month post-sales analyst support
Customization of the Report
In case of any queries or customization requirements, please connect with our sales team, who will ensure that your requirements are met.
Note: this report may need to undergo a final check or review and this could take about 48 hours.
Chapter Outline
Chapter 1 mainly introduces the statistical scope of the report, market division standards, and market research methods.
Chapter 2 is an executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market and its likely evolution in the short to mid-term, and long term.
Chapter 3 makes a detailed analysis of the Markets Competitive Landscape of the market and provides the market share, capacity, output, price, latest development plan, merger, and acquisition information of the main manufacturers in the market.
Chapter 4 is the analysis of the whole market industrial chain, including the upstream and downstream of the industry, as well as Porters five forces analysis.
Chapter 5 introduces the latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 6 provides the analysis of various market segments according to product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 7 provides the analysis of various market segments according to application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 8 provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 9 introduces the basic situation of the main companies in the market in detail, including product sales revenue, sales volume, price, gross profit margin, market share, product introduction, recent development, etc.
Chapter 10 provides a quantitative analysis of the market size and development potential of each region in the next five years.
Chapter 11 provides a quantitative analysis of the market size and development potential of each market segment (product type and application) in the next five years.
Chapter 12 is the main points and conclusions of the report.
Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Key Market Segments
1.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
1.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview
2.1 Global Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Landscape
3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Manufacturers (2019-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Manufacturers (2019-2024)
3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Sites, Area Served, Product Type
3.6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Situation and Trends
3.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
3.6.2 Global 5 and 10 Largest Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2019-2024)
6.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
6.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price by Type (2019-2024)
7 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Sales by Application (2019-2024)
7.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Application (2019-2024)
7.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
8 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segmentation by Region
8.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region
8.2 North America
8.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 BioMarin Pharmaceutical
9.1.1 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.1.4 BioMarin Pharmaceutical Business Overview
9.1.5 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.1.6 BioMarin Pharmaceutical Recent Developments
9.2 Sangamo Therapeutics
9.2.1 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.2.4 Sangamo Therapeutics Business Overview
9.2.5 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.2.6 Sangamo Therapeutics Recent Developments
9.3 Amicus Therapeutics
9.3.1 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.3.5 Amicus Therapeutics Business Overview
9.3.6 Amicus Therapeutics Recent Developments
9.4 Roche
9.4.1 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.4.4 Roche Business Overview
9.4.5 Roche Recent Developments
9.5 Pfizer
9.5.1 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 NightstaRx
9.6.1 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.6.4 NightstaRx Business Overview
9.6.5 NightstaRx Recent Developments
9.7 MeiraGTx
9.7.1 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.7.4 MeiraGTx Business Overview
9.7.5 MeiraGTx Recent Developments
9.8 Sarepta Therapeutics
9.8.1 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.8.4 Sarepta Therapeutics Business Overview
9.8.5 Sarepta Therapeutics Recent Developments
9.9 Neurocrine Biosciences
9.9.1 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.9.4 Neurocrine Biosciences Business Overview
9.9.5 Neurocrine Biosciences Recent Developments
9.10 Voyager Therapeutics
9.10.1 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.10.4 Voyager Therapeutics Business Overview
9.10.5 Voyager Therapeutics Recent Developments
9.11 Asklepios Biopharmaceutical
9.11.1 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.11.4 Asklepios Biopharmaceutical Business Overview
9.11.5 Asklepios Biopharmaceutical Recent Developments
10 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
10.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.3 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region
10.2.4 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2025-2030)
11.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) Forecast by Application
11.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.2 Key Market Segments
1.2.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Type
1.2.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview
2.1 Global Market Overview
2.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Estimates and Forecasts (2019-2030)
2.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Estimates and Forecasts (2019-2030)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Landscape
3.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Manufacturers (2019-2024)
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Market Share by Manufacturers (2019-2024)
3.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Average Price by Manufacturers (2019-2024)
3.5 Manufacturers Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Sites, Area Served, Product Type
3.6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Competitive Situation and Trends
3.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
3.6.2 Global 5 and 10 Largest Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Type (2019-2024)
6.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Market Share by Type (2019-2024)
6.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Price by Type (2019-2024)
7 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Sales by Application (2019-2024)
7.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) by Application (2019-2024)
7.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Growth Rate by Application (2019-2024)
8 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Segmentation by Region
8.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales Market Share by Region
8.2 North America
8.2.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Key Companies Profile
9.1 BioMarin Pharmaceutical
9.1.1 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.1.2 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.1.4 BioMarin Pharmaceutical Business Overview
9.1.5 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.1.6 BioMarin Pharmaceutical Recent Developments
9.2 Sangamo Therapeutics
9.2.1 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.2.2 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.2.4 Sangamo Therapeutics Business Overview
9.2.5 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.2.6 Sangamo Therapeutics Recent Developments
9.3 Amicus Therapeutics
9.3.1 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.3.2 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy SWOT Analysis
9.3.5 Amicus Therapeutics Business Overview
9.3.6 Amicus Therapeutics Recent Developments
9.4 Roche
9.4.1 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.4.2 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.4.4 Roche Business Overview
9.4.5 Roche Recent Developments
9.5 Pfizer
9.5.1 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.5.2 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.5.4 Pfizer Business Overview
9.5.5 Pfizer Recent Developments
9.6 NightstaRx
9.6.1 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.6.2 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.6.4 NightstaRx Business Overview
9.6.5 NightstaRx Recent Developments
9.7 MeiraGTx
9.7.1 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.7.2 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.7.4 MeiraGTx Business Overview
9.7.5 MeiraGTx Recent Developments
9.8 Sarepta Therapeutics
9.8.1 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.8.2 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.8.4 Sarepta Therapeutics Business Overview
9.8.5 Sarepta Therapeutics Recent Developments
9.9 Neurocrine Biosciences
9.9.1 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.9.2 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.9.4 Neurocrine Biosciences Business Overview
9.9.5 Neurocrine Biosciences Recent Developments
9.10 Voyager Therapeutics
9.10.1 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.10.2 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.10.4 Voyager Therapeutics Business Overview
9.10.5 Voyager Therapeutics Recent Developments
9.11 Asklepios Biopharmaceutical
9.11.1 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Basic Information
9.11.2 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Overview
9.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Market Performance
9.11.4 Asklepios Biopharmaceutical Business Overview
9.11.5 Asklepios Biopharmaceutical Recent Developments
10 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
10.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast
10.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Region
10.2.1 North America Market Size Forecast by Country
10.2.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.3 Asia Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region
10.2.4 South America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Country
10.2.5 Middle East and Africa Forecasted Consumption of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Country
11 Forecast Market by Type and by Application (2025-2030)
11.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Type (2025-2030)
11.1.1 Global Forecasted Sales of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Type (2025-2030)
11.1.3 Global Forecasted Price of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy by Type (2025-2030)
11.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Forecast by Application (2025-2030)
11.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Sales (Kilotons) Forecast by Application
11.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (M USD) Forecast by Application (2025-2030)
12 Conclusion and Key Findings